Canna~Fangled Abstracts

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease

By August 18, 2021August 30th, 2021No Comments
. 2021 Aug 18;22(16):8920.

doi: 10.3390/ijms22168920.

Claudio Giuliano 1, Miriam Francavilla 1, Gerardo Ongari 1, Alessandro Petese 1, Cristina Ghezzi 1, Nora Rossini 2, Fabio Blandini 1 2 3, Silvia Cerri 1
Affiliations 

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.

 

Keywords: 6-hydroxydopamine, cannabidiol, ciliary neurotrophic factor, neuroinflammation, phytocannabinoids, transient receptor potential vanilloid 1

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

References

    1. Dorsey E.R., Sherer T., Okun M.S., Bloem B.R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 2018;8:S3–S8. doi: 10.3233/JPD-181474. – DOI – PMC – PubMed
    1. Hirsch E.C., Standaert D.G. Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov. Disord. 2021;36:16–24. doi: 10.1002/mds.28075. – DOI – PubMed
    1. Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Munch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487. doi: 10.1038/nature21029. – DOI – PMC – PubMed
    1. Subramaniam S.R., Federoff H.J. Targeting microglial activation states as a therapeutic avenue in Parkinson’s disease. Front. Aging Neurosci. 2017;9:176. doi: 10.3389/fnagi.2017.00176. – DOI – PMC – PubMed
    1. Wang G., Zhou Y., Wang Y., Li D., Liu J., Zhang F. Age-associated dopaminergic neuron loss and midbrain glia cell phenotypic polarization. Neuroscience. 2019;415:89–96. doi: 10.1016/j.neuroscience.2019.07.021. – DOI – PubMed

Leave a Reply